Skip to Main Content

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (NAIVE)

Conditions

Diseases of the Musculoskeletal System | Immune System

What is the purpose of this trial?

The purpose of this study is to compare induction of influenza immunity after receipt of a currently recommended quadrivalent flu shot in two groups of patients who enter the trial with moderately to severely active SLE, ten having initiated anifrolumab at baseline in addition to standard of care, and ten receiving only standard of care. This study will help determine how anifrolumab affects the immune system response to the flu shot. If you meet the study requirements and are enrolled, you will be in this study no more than 18 weeks including a possible screening period of up to 2 weeks.

  • Trial with
    Oklahoma Medical Research Foundation
  • Start Date
    10/08/2021
  • End Date
    12/31/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/22/2021
  • Study HIC
    #2000030285